NCT05470140View on ClinicalTrials.gov

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

October 8, 2024

Study Completion Date

October 8, 2024

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

WU-NK-101

WU-NK-101 administered on Day 1, Day 8, and Day 15.

Trial Locations (9)

21201

University of Maryland, Baltimore

40299

Norton Health Care, Louisville

63110

Washington University, St Louis

91010

City of Hope, Duarte

94304

Stanford Healthcare, Palo Alto

97213

Providence Portland Medical Center, Portland

Unknown

Peter MacCallum Cancer Center, Melbourne

Royal Perth Hospital, Perth

Royal Prince Alfred Hospital, Sydney

All Listed Sponsors
lead

Wugen, Inc.

INDUSTRY